BACKGROUND: We conducted a phase I dose escalation study to evaluate the safety and immunologic response to peptide immunomodulatory vaccines GL-0810 (HPV16) and GL-0817 (MAGE-A3) in HPV16 and MAGE-A3-positive RM-SCCHN patients, respectively. METHODS: Three dose levels (500, 1,000, and 1,500 µg) of GL-0810 or GL-0817 with adjuvants Montanide (1.2 ml) and GM-CSF (100 µg/m2) were administered subcutaneously q2 weeks for a total of four vaccinations in HPV16 and MAGE-A3-positive RM-SCCHN patients, respectively. RESULTS: Nine and seven patients were enrolled in the HPV16 and MAGE-A3 cohorts, respectively. No dose-limiting toxicities were observed, and toxicity was predominantly local and grade 1 (erythema, pain, and itching at the injection site). In those patients who received all four vaccinations, 80 % (4/5) of the HPV16 cohort and 67 % (4/6) of the MAGE-A3 cohort developed antigen-specific T cell and antibody responses to the vaccine. Significant concordance between T cell and antibody responses was observed for both groups. No clear dose-response correlation was seen. All patients progressed by RECIST at first repeat imaging, except for one patient in the MAGE-A3 500 µg cohort who had stable disease for 10.5 months. The median PFS and OS for the MAGE-A3 cohorts were 79 and 183 days, respectively, and for the HPV16 cohort 80 and 196 days, respectively. CONCLUSIONS: GL-0810 and GL-0817 were well tolerated in patients with RM-SCCHN with T cell and antibody responses observed in the majority of patients who received all four vaccinations.
BACKGROUND: We conducted a phase I dose escalation study to evaluate the safety and immunologic response to peptide immunomodulatory vaccines GL-0810 (HPV16) and GL-0817 (MAGE-A3) in HPV16 and MAGE-A3-positive RM-SCCHN patients, respectively. METHODS: Three dose levels (500, 1,000, and 1,500 µg) of GL-0810 or GL-0817 with adjuvants Montanide (1.2 ml) and GM-CSF (100 µg/m2) were administered subcutaneously q2 weeks for a total of four vaccinations in HPV16 and MAGE-A3-positive RM-SCCHN patients, respectively. RESULTS: Nine and seven patients were enrolled in the HPV16 and MAGE-A3 cohorts, respectively. No dose-limiting toxicities were observed, and toxicity was predominantly local and grade 1 (erythema, pain, and itching at the injection site). In those patients who received all four vaccinations, 80 % (4/5) of the HPV16 cohort and 67 % (4/6) of the MAGE-A3 cohort developed antigen-specific T cell and antibody responses to the vaccine. Significant concordance between T cell and antibody responses was observed for both groups. No clear dose-response correlation was seen. All patients progressed by RECIST at first repeat imaging, except for one patient in the MAGE-A3 500 µg cohort who had stable disease for 10.5 months. The median PFS and OS for the MAGE-A3 cohorts were 79 and 183 days, respectively, and for the HPV16 cohort 80 and 196 days, respectively. CONCLUSIONS:GL-0810 and GL-0817 were well tolerated in patients with RM-SCCHN with T cell and antibody responses observed in the majority of patients who received all four vaccinations.
Authors: Caroline J Voskens; Duane Sewell; Ronna Hertzano; Jennifer DeSanto; Sandra Rollins; Myounghee Lee; Rodney Taylor; Jeffrey Wolf; Mohan Suntharalingam; Brian Gastman; John C Papadimitriou; Changwan Lu; Ming Tan; Robert Morales; Kevin Cullen; Esteban Celis; Dean Mann; Scott E Strome Journal: Head Neck Date: 2012-01-27 Impact factor: 3.147
Authors: M L Gillison; W M Koch; R B Capone; M Spafford; W H Westra; L Wu; M L Zahurak; R W Daniel; M Viglione; D E Symer; K V Shah; D Sidransky Journal: J Natl Cancer Inst Date: 2000-05-03 Impact factor: 13.506
Authors: David L A Figueiredo; Rui C M Mamede; Giulio C Spagnoli; Wilson A Silva; Marco Zago; Luciano Neder; Achim A Jungbluth; Fabiano P Saggioro Journal: Head Neck Date: 2010-09-30 Impact factor: 3.147
Authors: Johan Vansteenkiste; Marcin Zielinski; Albert Linder; Jubrail Dahabreh; Emilio E Gonzalez; Wojciech Malinowski; Marta Lopez-Brea; Tonu Vanakesa; Jacek Jassem; Haralabos Kalofonos; Jakub Perdeus; Reiner Bonnet; Jazeps Basko; Richard Janilionis; Bernward Passlick; Tom Treasure; Marc Gillet; Frédéric F Lehmann; Vincent G Brichard Journal: J Clin Oncol Date: 2013-05-28 Impact factor: 44.544
Authors: Sofia Lyford-Pike; Shiwen Peng; Geoffrey D Young; Janis M Taube; William H Westra; Belinda Akpeng; Tullia C Bruno; Jeremy D Richmon; Hao Wang; Justin A Bishop; Lieping Chen; Charles G Drake; Suzanne L Topalian; Drew M Pardoll; Sara I Pai Journal: Cancer Res Date: 2013-01-03 Impact factor: 12.701
Authors: Aimée R Kreimer; Mattias Johansson; Tim Waterboer; Rudolf Kaaks; Jenny Chang-Claude; Dagmar Drogen; Anne Tjønneland; Kim Overvad; J Ramón Quirós; Carlos A González; Maria José Sánchez; Nerea Larrañaga; Carmen Navarro; Aurelio Barricarte; Ruth C Travis; Kay-Tee Khaw; Nick Wareham; Antonia Trichopoulou; Pagona Lagiou; Dimitrios Trichopoulos; Petra H M Peeters; Salvatore Panico; Giovanna Masala; Sara Grioni; Rosario Tumino; Paolo Vineis; H Bas Bueno-de-Mesquita; Göran Laurell; Göran Hallmans; Jonas Manjer; Johanna Ekström; Guri Skeie; Eiliv Lund; Elisabete Weiderpass; Pietro Ferrari; Graham Byrnes; Isabelle Romieu; Elio Riboli; Allan Hildesheim; Heiner Boeing; Michael Pawlita; Paul Brennan Journal: J Clin Oncol Date: 2013-06-17 Impact factor: 44.544
Authors: Johannes A Veit; Daniela Heine; Julia Thierauf; Jochen Lennerz; Subasch Shetty; Patrick J Schuler; Theresa Whiteside; Dirk Beutner; Moritz Meyer; Inga Grünewald; Gerd Ritter; Sacha Gnjatic; Andrew G Sikora; Thomas K Hoffmann; Simon Laban Journal: Head Neck Date: 2016-02-13 Impact factor: 3.147
Authors: Stefan Hartmann; Muna Brisam; Stephan Rauthe; Oliver Driemel; Roman C Brands; Andreas Rosenwald; Alexander C Kübler; Urs D A Müller-Richter Journal: Oncol Lett Date: 2016-08-03 Impact factor: 2.967